Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
Company profile
Ticker
TARO
Exchange
Website
CEO
Uday Baldota
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
TARO stock data
News

Taro Pharmaceutical Indus: Q1 Earnings Insights
27 Jul 22
Taro Pharmaceutical Indus Q1 EPS $0.37 Down From $1.09 YoY, Sales $156.66M Up From $147.11M YoY
27 Jul 22
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
27 Jul 22
Earnings Scheduled For July 27, 2022
27 Jul 22
Stocks That Hit 52-Week Lows On Thursday
26 May 22
Press releases
Taro Provides Results for the Quarter Ended June 30, 2022
27 Jul 22
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022
26 Jul 22
Taro to Release First Quarter Results on July 27, 2022
26 Jul 22
Taro Provides Results for the Year Ended March 31, 2022
26 May 22
Taro to Announce Full Year Results on May 26, 2022
20 May 22
Calendar
25 Jul 22
13 Aug 22
31 Mar 23
Financial summary
Quarter (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2022
2.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 67 |
Opened positions | 7 |
Closed positions | 10 |
Increased positions | 22 |
Reduced positions | 27 |
13F shares | Current |
---|---|
Total value | 198.49M |
Total shares | 4.48M |
Total puts | 1K |
Total calls | 400 |
Total put/call ratio | 2.5 |
Largest owners | Shares | Value |
---|---|---|
Renaissance Technologies | 678.3K | $29.34M |
Krensavage Asset Management | 565.95K | $24.48M |
Dimensional Fund Advisors | 534.63K | $23.13M |
Brandes Investment Partners | 379.32K | $16.41M |
Acadian Asset Management | 326.43K | $14.09M |
FMR | 320.06K | $13.85M |
IVZ Invesco | 231.5K | $10.01M |
AMP Ameriprise Financial | 222.84K | $9.64M |
Eversept Partners | 220.29K | $9.53M |
Hotchkis & Wiley Capital Management | 191.82K | $8.3M |
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
acne, adulterated, Alchemee, anti, argued, assembled, attrition, authoritative, beautify, Biden, bifurcated, Bill, Bowne, CAL, card, chair, Chapter, CIT, clause, Clawback, cleanse, clearance, conclusion, condensed, Congressional, contempt, contrary, Coote, CSA, defective, Delaware, Differin, DPP, eager, endeavor, entirety, EPS, fact, faster, fifty, freestanding, FTC, gas, geopolitical, GRASE, greenhouse, heighten, Herzlya, host, inactive, inconsistency, inconsistent, indemnity, inferior, influential, injured, insufficient, intensification, Interbank, Japan, Kingdom, KK, layer, LLC, logistic, London, lost, Lynch, macroeconomic, magazine, MEEM, merchandise, merchant, Merrill, Mifalot, Minister, misbranded, MONETA, monograph, NADAC, necessitate, neoplastic, oassessing, odetermining, orecommending, override, Oxymetazoline, parallel, persuade, plaintiff, pose, posture, preemption, premarket, Proactiv, Proactive, ProactivMD, proceed, profession, proper, provisional, Prudential, quickly, randomized, Realty, recapture, recession, Reichman, rulemaking, Russia, Safer, shortage, skincare, slowdown, stolen, Sulfate, sunscreen, Suprep, survey, tangible, Task, Template, text, Today, TPC, transparency, transparent, trapped, Treasurer, Ukraine, unfair, unlawful, unsafe, unusable, unwilling, vaccinated, Vicept, voluntarily, wage, waive, war, William, yield, YK
Removed:
aa, advertise, advertised, advocacy, Analytical, API, Attestation, Avi, Avramoff, cancellation, cancelled, competence, consolidating, decide, feedback, FX, geographical, Herzliya, IDC, Imiquimod, instruct, Interdisciplinary, Itamar, Ivermectin, Karsenti, LLP, Magistrate, MBA, Michele, Micro, obligated, OSD, penned, Pertinent, Pharmacokinetic, Pharmacovigilance, preclude, preference, Princeton, progressively, promoted, QUANTITATIVE, ratified, reconsidered, recoverability, repeal, Secretary, Stern, Sulf, TDC, terminate, TIMETABLE, UNRESOLVED, Visosky, worked
Financial reports
Current reports
6-K
Current report (foreign)
28 Jul 22
6-K
Current report (foreign)
27 May 22
6-K
Current report (foreign)
28 Feb 22
6-K
Current report (foreign)
22 Feb 22
6-K
Current report (foreign)
27 Jan 22
6-K
Current report (foreign)
17 Dec 21
6-K
Current report (foreign)
1 Dec 21
6-K
Current report (foreign)
5 Nov 21
6-K
Current report (foreign)
4 Nov 21
6-K
Current report (foreign)
28 Oct 21
Registration and prospectus
SC TO-I/A
Issuer tender offer statement (amended)
19 Dec 19
SC TO-I/A
Issuer tender offer statement (amended)
17 Dec 19
SC TO-I/A
Issuer tender offer statement (amended)
3 Dec 19
SC TO-I
Issuer tender offer statement
15 Nov 19
SC TO-I/A
Issuer tender offer statement (amended)
29 Dec 13
SC TO-I/A
Issuer tender offer statement (amended)
23 Dec 13
SC TO-I/A
Issuer tender offer statement (amended)
11 Dec 13
SC TO-I/A
Issuer tender offer statement (amended)
8 Dec 13
SC TO-I
Issuer tender offer statement
24 Nov 13
SC 13E3/A
Going private transaction (amended)
7 Feb 13
Proxies
No filings
Other
CORRESP
Correspondence with SEC
14 May 20
UPLOAD
Letter from SEC
14 May 20
UPLOAD
Letter from SEC
6 May 20
CORRESP
Correspondence with SEC
9 Apr 20
UPLOAD
Letter from SEC
2 Mar 20
CORRESP
Correspondence with SEC
19 Feb 20
UPLOAD
Letter from SEC
20 Jan 20
CORRESP
Correspondence with SEC
2 Dec 19
UPLOAD
Letter from SEC
24 Nov 19
UPLOAD
Letter from SEC
23 Aug 15
Ownership
SC 13D/A
Taro Pharmaceutical Industries LTD
26 Nov 13
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
7 Feb 13
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
12 Aug 12
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
17 Oct 11
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
18 Jan 11
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / FRANKLIN RESOURCES ownership change
7 Nov 10
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
3 Nov 10
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
4 Oct 10
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
23 Sep 10
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
9 Sep 10
Patents
Utility
Stable Topical Compositions of Fenoldopam
10 Feb 22
The present disclosure is directed to a topical composition, e.g., a physically and chemically stable topical composition of Fenoldopam comprising about 0.1% to about 5% by weight of Fenoldopam or a pharmaceutically acceptable salt thereof, at least one polyacrylamide-type gelling agent, at least one cellulose-type gelling agent, and at least one solvent, wherein the Fenoldopam is substantially solubilized in the composition, and wherein the composition is stable for at least twelve months at 25° C. and 60% relative humidity.
Utility
Topical Montelukast Formulations
20 Jan 22
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Utility
Topical Montelukast Formulations
23 Dec 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Utility
Topical Montelukast formulations
16 Nov 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Utility
Topical Montelukast Formulations
5 Aug 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Transcripts
Reddit threads
Daily Discussion Thread - July 26th, 2022
26 Jul 22
Daily Discussion Thread - July 25th, 2022
25 Jul 22
Daily Discussion Thread - May 26th, 2022
26 May 22
Daily Discussion Thread - May 25th, 2022
25 May 22
Daily Discussion Thread - May 24th, 2022
24 May 22
Daily Discussion Thread - May 18th, 2022
18 May 22
Daily Discussion Thread - May 17th, 2022
17 May 22
Daily Discussion Thread - May 16th, 2022
16 May 22
Daily Discussion Thread - January 27th, 2022
27 Jan 22
Daily Discussion Thread - January 26th, 2022
26 Jan 22